Compare · GLP-1 agonist
Survodutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Survodutide | Tirzepatide | |
|---|---|---|
| Evidence | 7/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Survodutide
Survodutide (its lab code is BI 456906) is an experimental injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has more real human research behind it than most peptides sold online, including several carefully run trials that compared it against a placebo (a…
Tirzepatide
Tirzepatide is a once-a-week injectable peptide. You may know it by its brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Most of the compounds we write about here have thin evidence behind them. This one is different: it has been tested in large,…